• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

POZEN, Inc.

NASDAQ:POZN

$6.94 -$0.24 (-3.34%)

REAL-TIME: Last trade at

POZEN initiated with a Buy at Roth Capital

POZEN to Present at the Jefferies 2012 Global Healthcare Conference

POZEN to Present at the Jefferies 2012 Global Healthcare Conference

Research and Markets: Peptic Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2018

POZEN presents data from Phase l study

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)

Pozen Shares On The Rebound Since European Migraine Licensing Deal

21 Undervalued, Highly Shorted Stocks Being Bought Up By Hedge Funds

Antithrombotic/Anticoagulant Drugs: World Market 2012-2022

Pozen strikes commercialization deal for migraine drug

POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European Countries

POZEN enters into license agreement Desitin Arzneimittel

Pozen revenue down; good news on drug

POZEN announces positive results from Phase 3 trials of PA32540

Pozen, Inc. (POZN) Misses Q1 EPS by 3c

POZEN to update FY12 outlook

POZEN reports Q1 EPS (28c), consensus (26c)

POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results

9 Undervalued Healthcare Stocks Being Snapped Up By Hedge Funds

Morning Movers 04/27: (AWRE) (EXPE) (CRAY) (VIMC) Higher; (MXWL) (MDRX) (DECK) (TSYS) Lower

POZEN (POZN) Slammed as FDA May Limit PA32540 Treatment in Post-CABG Patients

POZEN falls 22.3%

POZEN initiated with a Buy at C.K. Cooper

Biotechnology And Drugs Stocks To Watch For Next Week

Top 10 Stocks With Increasing Sales And Profit Margins

10 Rallying High-Cash Stocks Being Bought Up By Hedge Funds

Pharma Bear Raids: Dendreon And Pozen

POZEN Announces May 1, 2012 Webcast of First Quarter 2012 Results

POZEN Announces May 1, 2012 Webcast of First Quarter 2012 Results

MAP Pharma: Still Potentially A Good Short Sell

POZEN management to meet with Wells Fargo

Needham to host a conference

The World Generic Market Report 2012

Pozen's CEO Responds to Questions About His Firm's Latest Developments and Positive Key Clinical Trial Results

Pozen's CEO Responds to Questions About His Firm's Latest Developments and Positive Key Clinical Trial Results

Pozen turns focus to NDA

Ulcer Drug Clears Late-stage Hurdles

Watson Pharmaceuticals, DISH Network Among Stocks Up on High Volume Thursday

StockReports.net Daily Watch List For March 21st 2012: Galena BioPharma &Pozen Inc

See More Articles...